Marshall Wace’s Ibere Pharmaceuticals IBER Stock Holding History

Marshall Wace’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-539,807	Closed	-$5.45M	–	3475
2022 Q4	$5.45M	Hold	539,807	–	–	0.01%	1139
2022 Q3	$5.35M	Buy	539,807 +7,622	+1%	+$75.2K	0.01%	1318
2022 Q2	$5.22M	Hold	532,185	–	–	0.01%	1308
2022 Q1	$5.22M	Buy	532,185 +800	+0.2%	+$7.79K	0.01%	1332
2021 Q4	$5.17M	Buy	531,385 +81,391	+18%	+$791K	0.01%	1326
2021 Q3	$4.36M	Hold	449,994	–	–	0.02%	1014
2021 Q2	$4.35M	Buy	+449,994	New	+$4.38M	0.02%	930

Marshall Wace's IBER Position: Q1 2023 in Review

Marshall Wace sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 539,807 shares — an estimated $5.45M sold.

Marshall Wace first reported a position in IBER in Q2 2021 and held it in 7 quarters. The position peaked at $5.45M in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

Marshall Wace reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Marshall Wace sold 539,807 Ibere Pharmaceuticals shares in Q1 2023, an estimated $5.45M.
Marshall Wace first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 7 quarters.
Marshall Wace's Ibere Pharmaceuticals position peaked at $5.45M in Q4 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Marshall Wace's 13F filing for Q1 2023, filed 15 May 2023.